The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of everolimus monotherapy in the palliative treatment of patients with metastatic transitional cell carcinoma (TCC) after failure of platinum-based therapy: Activity and biomarkers.
E. Seront
No relevant relationships to disclose
B. Sautois
No relevant relationships to disclose
S. Rottey
No relevant relationships to disclose
L. A. D'Hondt
No relevant relationships to disclose
J. Canon
No relevant relationships to disclose
J. Vandenbulcke
No relevant relationships to disclose
N. Whenham
No relevant relationships to disclose
J. C. Goeminne
No relevant relationships to disclose
O. Feron
No relevant relationships to disclose
J. H. Machiels
Consultant or Advisory Role - Boehringer Ingelheim; Genmab; Merck Serono
Research Funding - Merck Serono; Novartis